6.38

11.14% -0.80

After Hours: 6.38

Emergent Biosolutions Inc (EBS)

Overview News Price History Option Chain Financials Discussions Forecast

Emergent Biosolutions Inc stock is traded at $6.38, with a volume of 2.24M. It is down -11.14% in the last 24 hours and down -5.48% over the past month. Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.

Previous Close:

$7.18

Open:

$6.64

24h Volume:

2.24M

Relative Volume:

1.77

Market Cap:

$327.12M

Revenue:

$676.80M

Net Income/Loss:

$-8.60M

P/E Ratio:

-22.55

EPS:

-0.2829

Net Cash Flow:

$135.40M

1W Performance:

-9.63%

1M Performance:

-5.48%

6M Performance:

-25.99%

1Y Performance:

-32.13%

1-Day Range:

$6.1505

$6.73

1-Week Range:

$6.1505

$7.33

52-Week Range:

$4.36

$14.06

Emergent Biosolutions Inc Stock (EBS) Company Profile

Name

Emergent Biosolutions Inc

Sector

Healthcare (1052)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

240-631-3200

Address

300 PROFESSIONAL DR, GAITHERSBURG, MD

Employee

900

Twitter

@emergentbiosolu

Next Earnings Date

2026-11-02

Latest SEC Filings

EBS's Discussions on Twitter

Compare EBS vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EBS Emergent Biosolutions Inc	6.38	327.12M	676.80M	-8.60M	135.40M	-0.2829
TAK Takeda Pharmaceutical Co Adr	19.67	62.84B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	41.50	48.40B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	10.13	44.55B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	79.38	32.80B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	533.12	22.87B	3.17B	1.29B	1.01B	27.09

Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-21-26	Resumed	JP Morgan	Underweight
Dec-30-24	Initiated	H.C. Wainwright	Buy
Aug-22-24	Initiated	Rodman & Renshaw	Buy
Mar-07-24	Upgrade	The Benchmark Company	Hold → Buy
Nov-20-23	Resumed	JP Morgan	Underweight
Aug-29-23	Downgrade	The Benchmark Company	Buy → Hold
Apr-10-23	Upgrade	The Benchmark Company	Hold → Buy
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-10-22	Downgrade	The Benchmark Company	Buy → Hold
Apr-29-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-20-22	Upgrade	The Benchmark Company	Hold → Buy
Nov-08-21	Downgrade	The Benchmark Company	Buy → Hold
May-05-21	Downgrade	Argus	Buy → Hold
Apr-07-21	Initiated	The Benchmark Company	Buy
Feb-24-21	Upgrade	Chardan Capital Markets	Neutral → Buy
Feb-19-21	Downgrade	Chardan Capital Markets	Buy → Neutral
Jan-08-21	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-14-20	Resumed	JP Morgan	Neutral
Jul-31-20	Reiterated	Chardan Capital Markets	Buy
Sep-12-19	Initiated	Guggenheim	Buy
Sep-04-19	Upgrade	Wells Fargo	Market Perform → Outperform
Nov-02-18	Upgrade	Goldman	Neutral → Buy
Aug-03-18	Reiterated	Chardan Capital Markets	Buy
Jun-13-18	Initiated	Argus	Buy
Apr-25-18	Downgrade	Wells Fargo	Outperform → Market Perform
Jan-24-18	Initiated	Goldman	Neutral
Jan-16-18	Reiterated	Chardan Capital Markets	Buy
Jun-28-16	Reiterated	Singular Research	Buy
Apr-15-16	Initiated	Chardan Capital Markets	Buy
Mar-28-16	Initiated	Singular Research	Buy
Feb-19-16	Initiated	Wells Fargo	Outperform
May-15-14	Initiated	Summer Street Research	Buy
May-31-11	Reiterated	WBB Securities	Strong Buy
Jan-10-11	Reiterated	Wedbush	Outperform
Nov-05-10	Reiterated	Wedbush	Outperform
Aug-18-10	Upgrade	WBB Securities	Buy → Strong Buy
Aug-06-10	Reiterated	Caris & Company	Buy

View All

Emergent Biosolutions Inc Stock (EBS) Latest News

Oct 16, 2026

Emergent BioSolutions stock falls as CFO plans retirement - Investing.com

Oct 16, 2026

Emergent BioSolutions CFO to retire, treasurer named interim - Investing.com

Oct 16, 2026

Emergent BioSolutions Inc. Announces Chief Financial Officer Changes - marketscreener.com

Oct 16, 2026

Emergent BioSolutions (EBS) CFO Richard Lindahl to Retire, Shares Drop Premarket - GuruFocus

Oct 16, 2026

Emergent Biosolutions Announces Retirement of Richard S. Lindahl as Executive Vice President, Effective December 31, 2026 - www.marketscreener.com

Oct 16, 2026

Emergent BioSolutions CFO Richard Lindahl to Retire, Frank Vargo Named Interim Successor - citybiz

Oct 16, 2026

Emergent BioSolutions (EBS) CFO Richard Lindahl to Retire; Inter - GuruFocus

Oct 16, 2026

Emergent BioSolutions CFO Richard Lindahl to retire end of 2026 - StreetInsider

Oct 16, 2026

Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl - Business Wire

Oct 16, 2026

Oct 15, 2026

Press Release: Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026 - Moomoo

Oct 15, 2026

Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026 - Business Wire

Oct 15, 2026

Oct 07, 2026

Emergent BioSolutions Director Donald W. DeGolyer Sells 17,800 Shares on October 7, 2026 - Kalkine Media

Oct 07, 2026

Form 4 Emergent Biosolutions Inc For: 7 October By Investing.com - Investing.com Canada

Oct 07, 2026

Emergent BioSolutions director DeGolyer sells $126k in shares - Investing.com

Oct 07, 2026

Director Donald DeGolyer proposes selling 17,800 Emergent BioSolutions (NYSE: EBS) shares. - Stock Titan

Oct 07, 2026

To cover stock-award taxes, an Emergent BioSolutions (EBS) director sold 17,800 shares under a trading plan. - Stock Titan

Oct 07, 2026

Oct 06, 2026

EBS5025998 Bond Profile: Coupon and Redemption - TradingView

Oct 06, 2026

Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock? - Zacks Investment Research

Oct 06, 2026

Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock? - Yahoo Finance

Oct 06, 2026

Oct 05, 2026

Form 4 Emergent Biosolutions Inc For: 5 October By Investing.com - Investing.com South Africa

Oct 05, 2026

Emergent BioSolutions (EBS) SVP, Products Business Paul Williams Sells 3,000 Shares - GuruFocus

Oct 05, 2026

Form 4 Emergent Biosolutions Inc For: 5 October By Investing.com - Investing.com UK

Oct 05, 2026

Under a trading plan, Emergent BioSolutions (EBS) officer Williams sold 3,000 shares at $6.53. - Stock Titan

Oct 05, 2026

Oct 01, 2026

Emergent BioSolutions Inc. Common Stock (NYSE:EBS) Detailed Stock Data - The Chronicle-Journal

Oct 01, 2026

A 3,000-share sale is proposed by Emergent BioSolutions (EBS) officer Paul Williams. - Stock Titan

Oct 01, 2026

Sep 26, 2026